PepGen Inc.

NASDAQ:PEPG

Biotechnology

Healthcare
$3.83 +5.29%

+$0.09 today

Market cap
$265.27M
Beta
1.93
P/E (TTM)
-1.6
EPS (TTM)
-$1.12
52W Low $1.01High $7.80

Volume 3.39M

Average 1.37M

PEPG Short-term Investments

Marketable securities and deposits the company expects to convert to cash within a year.

PepGen Inc.NASDAQ: PEPG

Short-term Investments · Q1 FY2026 · quarter ended Mar 2026

Short-term investments rises 66.5% from a year ago

Short-term investments stood at $90.15M at the end of Q1 FY2026, up 66.5% from a year earlier and up 2.5% from the prior quarter.

Context

  • Short-term investments amounted to 57.7% of total assets at the end of Q1 FY2026, up 15.2 pp from a year earlier.
  • Short-term investments increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether short-term investments keeps rising in the next quarterly balance sheet after a +66.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$90.15M+2.5% QoQ
Last fiscal yearDec 2025
$87.94M+24.3% YoY
Year agoMar 2025
$54.15M+66.5% since
Short-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+66.5%——
1 year+24.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Short-term Investments history

USD · from the balance sheet

Latest · FY2025
87.94M USD
Year-over-year change
+24.3%

Short-term Investments vs competitors

How PEPG compares with its peers on the latest reported figures

  • Peers report in different currencies, so short-term investments is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +66.5% is the highest of 7, against a peer median of -31.8%.
  • Short-term investments amounts to 57.7% of total assets for PEPG, versus a peer median of 54.0%.
PEPG Competitors
Short-term Investments for PEPG and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NKTXNkarta, Inc.Mar 2026$203.07M USD-4.6%-9.1%54.6%
FATEFate Therapeutics, Inc.Mar 2026$135.25M USD-30.8%-25.2%47.5%
ALECAlector, Inc.Mar 2026$129.55M USD-59.1%-30.2%54.0%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026$112.56M USD-1.2%+47.3%77.9%
PEPGPepGen Inc.Mar 2026$90.15M USD+66.5%—57.7%
CRDFCardiff Oncology, Inc.Mar 2026$37.51M USD-32.8%-22.8%76.3%
MOLNMolecular Partners AGMar 2026CHF 14.52M CHF-70.7%-59.9%16.6%
ELTXElicio Therapeutics, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding PEPG) —-31.8%-24.0%54.0%

Competitors are the stored peer set for PEPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents132.9M181.75M80.77M49.42M60.51M
Short-term Investments0029.63M70.77M87.94M
Net Receivables4.74M58K000
Inventory00000
Other Current Assets04.27M2.27M3.57M2.51M
Total Current Assets139.99M186.08M112.68M123.76M150.96M
Property, Plant & Equipment (Net)636K29.88M28.38M25.15M21.02M
Goodwill00000
Intangible Assets00000
Long-term Investments1.47M0000
Tax Assets00000
Other Non-current Assets1.55M1.47M1.99M1.97M1.92M
Total Non-current Assets3.66M31.36M30.37M27.12M22.94M
Total Assets143.64M217.44M143.05M150.88M173.91M
Account Payables3.24M1.36M1.01M1.75M822K
Short-term Debt00000
Tax Payables02.57M000
Deferred Revenue00000
Other Current Liabilities1.21M2.44M2.37M3.62M4.66M
Total Current Liabilities10.32M18.83M17.53M16.7M12.65M
Long-term Debt000013.82M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities226K0000
Total Non-current Liabilities226K18.98M17.1M15.57M13.82M
Total Liabilities10.55M37.81M34.63M32.26M26.46M
Common Stock02K2K3K7K
Retained Earnings(33.75M)(102.86M)(181.48M)(271.46M)(361.12M)
Accumulated OCI17K(81K)34K23K11K
Other Stockholders Equity00000
Minority Interest00000
Total Equity133.09M179.63M108.42M118.62M147.44M
Total Debt024.53M20.1M18.66M17M
Net Debt(132.9M)(157.22M)(60.67M)(30.76M)(43.51M)

PepGen Inc.

NASDAQ:PEPG

Intrinsic Alpha fair value

Locked

Current Price

$3.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.